Summary The endogenous APP gene was disrupted in these animals by homologous recombination. At birth, mice homozygous for the targeted allele are viable and do not display any gross physical or ...

Can brain amyloid reduction be used as a surrogate biomarker of clinical benefit? This is a hotly debated question in the field (see Dec 2024 discussion). A recent post hoc analysis of Phase 3 ...

CAR-T cell therapy has practically become a household name, given its success in taking down blood cancers. The chimeric antigen receptors used in this type of cell therapy are designed to sic killer ...

This humanized IgG1 antibody inhibits an immune checkpoint protein called programmed death ligand, aka PD-L1, stimulating the immune system. Checkpoint inhibitors, including other antibodies, are ...

Amyloid plaques drive the spread of tangles throughout a person’s brain, but much about this process remains mysterious. At this year’s AD/PD conference in Copenhagen, Denmark, speakers showed PET ...

Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...

AAIC 2025 in Toronto featured more than 6,000 poster and oral presentations. Woven through 17 stories, Alzforum reporters traced some of the latest developments in clinical trials, biomarkers, and ...

We couldn’t be more excited to unveil our redesigned website, and can’t wait to have you dive into all the new features and content we’ve developed! We know we still have a few bugs to work out, and ...

Just as Eisai notches wins in its campaign for lecanemab approval around the world—last month in the European Union, this week in Mexico—a dozen research and clinical leaders called on the U.S. FDA ...

Fewer than 1 percent of amyloid-targeted monoclonal antibodies like lecanemab and donanemab reach their targets in the brain. The excess doses required to make up for this problem raise the risk of ...

A top researcher’s fall from grace sends shock waves through the scientific community. Such is the case with neuropathologist Eliezer Masliah, who stands accused of image falsification spanning 26 ...

On Tuesday September 10, Francisco Lopera died of cancer at his home in Medellin, Colombia. He was 73, and only just beginning to see his life’s work come to fruition. In fact, Lopera still had much ...